Provided by Tiger Fintech (Singapore) Pte. Ltd.

Eterna Therapeutics Inc.

0.2160
+0.01115.42%
Post-market: 0.2061-0.0099-4.58%17:59 EDT
Volume:210.79K
Turnover:43.59K
Market Cap:13.43M
PE:-0.07
High:0.2200
Open:0.2040
Low:0.1900
Close:0.2049
Loading ...

Ernexa Therapeutics Announces New Data to be Presented at AACR Annual Meeting 2025

GlobeNewswire
·
22 Apr

Ernexa Therapeutics Closes New Funding Round

GlobeNewswire
·
03 Apr

Eterna appoints Zeldis, Sather to scientific advisory board

TIPRANKS
·
28 Jan

Eterna Therapeutics Announces Expansion of Scientific Advisory Board

THOMSON REUTERS
·
28 Jan

Press Release: Eterna Therapeutics Announces Expansion of Scientific Advisory Board

Dow Jones
·
28 Jan

Eterna Therapeutics Reports Positive Preclinical Results for Cancer Therapy ERNA-101; Shares Jump

MT Newswires Live
·
14 Jan

Eterna announces preclinical study results on ERNA-101

TIPRANKS
·
14 Jan

Eterna Therapeutics Inc - Erna-101 Expected to Enhance Efficacy of CAR-T and Car-Nk Therapies

THOMSON REUTERS
·
14 Jan

Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product Erna-101 in Ovarian Cancer

THOMSON REUTERS
·
14 Jan

Eterna Therapeutics Inc - Erna-101 Treated Mice Show Significant Survival Advantage

THOMSON REUTERS
·
14 Jan

Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer

GlobeNewswire
·
14 Jan

Eterna Therapeutics Announces Appointment of DR. Elena Ratner to Board of Directors

THOMSON REUTERS
·
09 Jan

Press Release: Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors

Dow Jones
·
09 Jan

BRIEF-Eterna Therapeutics Inc - Receives Nasdaq Notice For Minimum Bid Price Non-Compliance

Reuters
·
04 Jan

Eterna launches research to evaluate ERNA-101

TIPRANKS
·
03 Dec 2024

Eterna: to Investigate Ability of Erna-101 to Induce, Modulate Antitumor Immunity in Ovarian Cancer, Breast Cancer Models Through Research

THOMSON REUTERS
·
03 Dec 2024

Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate’s (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models

GlobeNewswire
·
03 Dec 2024

BRIEF-Eterna Therapeutics Announces Up To $1 Million Stock Repurchase Program

Reuters
·
25 Nov 2024

Eterna Therapeutics announces up to $1 million stock repurchase program

seekingalpha
·
25 Nov 2024

Eterna Therapeutics Announces up to $1 Million Stock Repurchase Program

THOMSON REUTERS
·
25 Nov 2024